Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Wed, 15-Apr 2:30 AM ET)
Mizuho Securities Gives a Buy Rating to Alcon (ALC)
TipRanks (Wed, 15-Apr 2:17 AM ET)
Systane Partners with Toronto Blue Jays to Raise Dry Eye Awareness Across Canada
Market Chameleon (Wed, 8-Apr 3:33 AM ET)
Business Wire (Tue, 7-Apr 12:15 PM ET)
Alcon Launches Clareon TruPlus, Enhanced Design Monofocal and Toric IOLs, at ASCRS 2026
Business Wire (Mon, 6-Apr 8:03 AM ET)
Alcon Publishes Agenda for 2026 Annual General Meeting
Business Wire (Thu, 2-Apr 4:30 PM ET)
Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement
Business Wire (Mon, 16-Mar 4:57 PM ET)
Market Chameleon (Mon, 2-Mar 3:22 AM ET)
Alcon Surpasses 175 Million IOLs Implanted Globally
Business Wire (Mon, 2-Mar 8:03 AM ET)
Alcon Delivers Strong Fourth-Quarter 2025 Topline Growth as New Product Launches Accelerate Sales
Business Wire (Tue, 24-Feb 4:30 PM ET)
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Alcon trades on the NYSE stock market under the symbol ALC.
As of April 20, 2026, ALC stock price declined to $80.30 with 704,290 million shares trading.
ALC has a beta of 0.71, meaning it tends to be less sensitive to market movements. ALC has a correlation of 0.17 to the broad based SPY ETF.
ALC has a market cap of $39.72 billion. This is considered a Large Cap stock.
Last quarter Alcon reported $3 billion in Revenue and $.78 earnings per share. This fell short of revenue expectation by $-7 million and missed earnings estimates by -$.06.
In the last 3 years, ALC traded as high as $101.10 and as low as $69.44.
The top ETF exchange traded funds that ALC belongs to (by Net Assets): EQTY, DFIV, DFAI, DFIC, DFAX.
ALC has underperformed the market in the last year with a price return of -12.9% while the SPY ETF gained +36.0%. ALC has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +1.6% and +7.7%, respectively, while the SPY returned +2.7% and +8.1%, respectively.
ALC support price is $79.89 and resistance is $82.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALC shares will trade within this expected range on the day.